Syndax gains additional indication for Revuforj in acute myeloid leukemia

[Fda Approved Stamp]
atakan

* The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX [https://seekingalpha.com/symbol/SNDX]) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic mutation.
* The indication [https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation] is for individuals with the disease who have the susceptible nucleophosmin 1 (_NPM1_) mutation and no other treatment options.
* Revuforj was first approved in 2024 for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.
* The menin inhibitor's new indication was granted based on results from a single-arm cohort of an open-label trial. The complete remission with partial hematological recovery rate was 23.1% and the median duration was 4.5 months.

MORE ON SYNDAX PHARMACEUTICALS

* Making Money In Biotech Stocks [https://seekingalpha.com/article/4828961-making-money-in-biotech-stocks]
* Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC [https://seekingalpha.com/article/4821782-syndax-pharmaceuticals-revumenib-pdufa-review-mnpm1-aml-and-move-towards-mss-crc]
* Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript [https://seekingalpha.com/article/4818706-syndax-pharmaceuticals-inc-sndx-presents-at-citis-biopharma-back-to-school-conference]
* Syndax resumed with Buy at Stifel on newly launched drugs [https://seekingalpha.com/news/4493767-syndax-stock-resumed-buy-stifel]
* Syndax jumps after Q2 beat; Citi issues upside catalyst watch [https://seekingalpha.com/news/4478889-syndax-stock-as-citi-issues-catalyst-watch]